A phase II dose-ranging study of palonosetron in Japanese patients receiving moderately emetogenic chemotherapy, including anthracycline and cyclophosphamide-based chemotherapy.

Abstract

BACKGROUND The 5-HT(3) receptor antagonists (RAs) help maintain the standard of care, in various combinations with other agents, for prevention of chemotherapy-induced nausea and vomiting (CINV). Palonosetron is a new generation 5-HT(3) RA with indication not only acute but also delayed nausea and vomiting induced by moderately emetogenic chemotherapy (MEC… (More)
DOI: 10.1093/annonc/mdp243

Topics

Cite this paper

@article{Segawa2009API, title={A phase II dose-ranging study of palonosetron in Japanese patients receiving moderately emetogenic chemotherapy, including anthracycline and cyclophosphamide-based chemotherapy.}, author={Yoshihiko Segawa and Kenjiro Aogi and Kazuo Inoue and Michio Sano and Ikuo Sekine and Yutaka Tokuda and Hiroshi Isobe and Tosjio Ogura and Masaya Tsuboi and Shinji Atagi}, journal={Annals of oncology : official journal of the European Society for Medical Oncology}, year={2009}, volume={20 11}, pages={1874-80} }